The Diagnosis and Management of Hirsutism

Adrienne B. Neithardt; Randall B. Barnes

doi:10.1055/s-2003-43306

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2003; 21(3): 285-294
DOI: 10.1055/s-2003-43306

The Diagnosis and Management of Hirsutism

Adrienne B. Neithardt¹ , Randall B. Barnes²

¹Department of Obstetrics and Gynecology, Northwestern University Medical School and Prentice Women's Hospital, Chicago, Illinois
²Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Northwestern University Medical School and Prentice Women's Hospital, Chicago, Illinois

Abstract

ABSTRACT

Approximately 10% of women of childbearing age are hirsute, which is defined as the presence of coarse terminal hairs in androgen-dependent areas on the face and body. It not only is a source of psychological discomfort but also may be a sign of an underlying medical condition. This article reviews the pathophysiology, diagnosis, evaluation, and treatment of hirsutism.

KEYWORDS

Hirsutism - hyperandrogenism - antiandrogens - hair removal

Full Text

References

REFERENCES

1 Deplewski D, Rosenfield R. Role of hormones in pilosebaceous unit development. Endocr Rev . 2000; 21 362-392
2 Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab . 1961; 21 1440-1447
3 Knoochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab . 1998; 83 3078-3082
4 Azziz R, Carmina E, Sawaya M. Idiopathic hirsutism. Endocr Rev . 2000; 21 347-362
5 Paus R, Cotsarelis G. Mechanisms of disease: the biology of hair follicles. N Engl J Med . 1999; 341 491-497
6 Habif T P. Clinical Dermatology. 3rd ed. St. Louis: Mosby-Year Book 1996: 739-740
7 Jaworsky C, Gilliam A C. Update on dermatopathology: immunology of the human hair follicle. Dermatol Clin . 1999; 17 561-569
8 Gilliam A C, Kremer I B, Yosida Y. et al . The human hair follicle: a reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure. J Invest Dermatol . 1998; 110 422-427
9 Staricco R G. Amelanotic melanocytes in the outer sheath of the human hair follicle and their role in the repigmentation of regenerated epidermis. Ann N Y Acad Sci . 1963; 100 239-255
10 Paus R. Immunology of the hair follicle. In: Bos JD, ed. Skin Immune System 2nd ed. Boca Raton, FL: CRC Press 1997: 377-398
11 Christoph T, Muller-Rover S, Audring H. et al . The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol . 2000; 142 862-873
12 Speroff L, Glass R H, Kase N G. Clinical Gynecologic Endocrinology and Infertility 6th ed. Philadelphia: Lippincott Williams & Wilkins; 1999 40-51: 523-556
13 Chuong C-M. Molecular Basis of Epithelial Appendage Morphogenesis: Molecular Biology Intelligence Unit 1. Austin, TX: RG Landes; 1998
14 Zhou P, Byrne C, Jacobs J, Fuchs E. Lymphoid enhancing factor 1 directs hair follicle patterning and epithelial cell fate. Genes Dev . 1995; 9 100-113
15 Hardy M H. The secret life of the hair follicle. Trends Genet . 1992; 8 55-61
16 Ebling F J. Hair. J Invest Dermatol . 1976; 67 98-105
17 Messenger A G. The control of hair growth: an overview. J Invest Dermatol . 1993; 101 4S-9S
18 Lindner G, Botchkarev V A, Botchkareva N V. et al . Analysis of apoptosis during hair follicle regression. Am J Pathol . 1997; 151 1601-1617
19 Lorenzo E M. Familial study of hirsutism. J Clin Endocrinol . 1970; 31 556-564
20 Hatch R, Rosenfield R L, Kim M H, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol . 1981; 140 815-830
21 Hock D, Seifer D. New treatments of hyperandrogenism and hirsutism. Obstet Gynecol Clin . 2000; 27 567-581
22 Berek J, Adash E, Hillard P. Novaks' Gynecology. 12th ed. Baltimore: Williams & Wilkins 1996: 834-836
23 Ryan K J. Biological aromatization of steroids. J Biol Chem . 1959; 234 234-268
24 Ryan K J, Smith O W. Biogenesis of steroid hormones in the human ovary. Recent Prog Horm Res . 1965; 21 367
25 Azziz R, Zacur H A. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. J Clin Endocrinol Metab . 1989; 69 577-584
26 Glickman S P, Rosenfield R L. Androgen metabolism by isolated hairs from women with idiopathic hirsutism is usually normal. J Invest Dermatol . 1984; 82 62-66
27 Wiebe R H, Morris C V. Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet Gynecol . 1984; 63 12-14
28 Barnes R B. Diagnosis and therapy of hyperandrogenism. Baillieres Clin Obstet Gynaecol . 1997; 11 369-396
29 Lobo R A. Ovarian hyperandrogenism and androgen-producing tumors. Endocrinol Metab Clin North Am . 1991; 20 773-805
30 Ehrman D A, Barnes R B, Rosenfield R L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev . 1995; 16 322-353
31 Barnes R B, Rosenfield R L, Burstein S, Ehrman D A. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med . 1989; 320 559-565
32 Rosenfield R L, Barnes R B, Ehrman D A. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab . 1994; 79 1686-1692
33 Chetkowski R J, Defazio J, Shamonki I. et al . The incidence of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency in hirsute women. J Clin Endocrinol Metab . 1984; 58 595-598
34 Kutten F, Coullin P, Girard F. et al . Late-onset adrenal hyperplasia in hirsutism. N Engl J Med . 1985; 313 224-231
35 White P C, New M I, Dupont B. Congenital adrenal hyperplasia. N Engl J Med . 1987; 316 1580-1586
36 Carmina E. Prevalence of idiopathic hirsutism. Eur J Endocrinol . 1998; 139 421-423
37 Mowszowicz I, Melanitou E, Doukani A. et al . Androgen binding capacity and 5α-reductase activity in pubic skin fibroblasts from hirsute patients. J Clin Endocrinol Metab . 1983; 56 1209-1213
38 Couzinet B, Pholsena M, Young J, Schaison G. The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin Endocrinol (Oxf) . 1993; 39 157-162
39 Thorneycroft I H. Current issues in oral contraceptive therapy: update on androgenicity. Am J Obstet Gynecol . 1999; 180 288-294
40 Azziz R, Ochoa T M, Bradley Jr L E. et al . Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J Clin Endocrinol Metab . 1995; 80 3406-3411
41 Heiner J S, Greendale G A, Kawakami A K. et al . Comparison of a gonadotropin-releasing hormone agonist and a low does oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab . 1995; 80 3412-3418
42 Chang R J, Laufer L R, Meldrum D R. et al . Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab . 1983; 56 897-903
43 Andreyko J L, Monroe S E, Jaffe R B. The treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin). J Clin Endocrinol Metab . 1986; 63 854-859
44 Steingold K, De Ziegler D, Cedars M. et al . Clinical and hormonal effect of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab . 1987; 65 773-778
45 Rittmaster R S. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide. J Clin Endocrinol Metab . 1988; 67 651-655
46 Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovarian syndrome and idiopathic hirsutism. Fertil Steril . 1991; 56 427-433
47 Elkind-Hirsch K E, Anania C, Mack M, Malinak R. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism. Fertil Steril . 1995; 63 970-978
48 Carr B R, Breslau N A, Givens C. et al . Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for the treatment of hirsutism: a clinical research center study. J Endocrinol Metab . 1995; 80 1169-1178
49 Yucelten D, Erenus M, Gurbuz O, Durmusoglu F. Recurrence rates of hirsutism after 3 different antiandrogen therapies. J Am Acad Dermatol . 1999; 41 64-68
50 Rittmaster R S. Clinical review 73: medical treatment of androgen dependent hirsutism. J Clin Endocrinol Metab . 1995; 80 2559-2563
51 Carmina E, Lobo R A. Peripheral androgen blockade versus glandular suppression in the treatment of hirsutism. Obstet Gynecol . 1991; 78 845-849
52 Mowszowicz I, Wright F, Vincens M. et al . Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem . 1984; 20 757-761
53 Hammerstein J, Meckies J, Leo-Rossberg I. et al . Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem . 1975; 6 827-836
54 Young R L, Goldzieher J W, Elkind-Hirsch K. The endocrine effects of spironolactone used as an antiandrogen. Fertil Steril . 1987; 48 223-228
55 Lobo R A, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril . 1985; 43 200-205
56 Evans D J, Burke C W. Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovarian syndrome. J R Soc Med . 1986; 79 451-453
57 Barth J H, Cherry C A, Wojnarowaka F, Dawber R P. Spironolactone is an effective and well tolerated systemic anti-androgen therapy for hirsute women. J Clin Endocrinol Metab . 1989; 68 966-970
58 McMullen G R, Van Herle J A. Hirsutism and the effectiveness of spironolactone in its management. J Endocrinol Invest . 1993; 16 925-932
59 Cumming D C, Yang J C, Rebar R W, Yen S SC. Treatment of hirsutism with spironolactone. JAMA . 1982; 247 1295-1298
60 Chapman M G, Dowsett M, Dewhurst C J, Jeffcoate S L. Spironolactone in combination with an oral contraceptive: an alternative treatment of hirsutism. Br J Obstet Gynaecol . 1985; 92 983-985
61 Simard J, Luthy I, Guay J, Belanger A, Labrie F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol . 1986; 44 261-270
62 Muderris I I, Bayram F, Sahin Y, Kelestimur F. A comparison of two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism. Fertil Steril . 1997; 68 644-647
63 Erenus M, Gurbuz O, Durmusoglu F. et al . Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil Steril . 1994; 61 613-616
64 Moghetti P, Tosi F, Tosi A. et al . Comparison of spironolactone, flutamide and finasteride in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab . 2000; 85 90-94
65 Cusan L, Dupont A, Gomez J L, Tremblay R R, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril . 1994; 61 281-287
66 Lapointe J, Fournier A, Richard V, Labrie C. Androgens down-regulate bcl-2 protooncogenes expression in ZR-75-1 human breast cancer cells. Endocrinology . 1999; 140 416-421
67 Tolino A, Petrone A, Sarnacchiaro F. et al . Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril . 1996; 66 61-65
68 Fruzzetti F, Delorenzo D, Parini D, Ricci C. Effects of finasteride, a 5α-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J Clin Endocrinol Metab . 1994; 79 831-835
69 Moghetti P, Castello R, Magnani C M. et al . Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab . 1994; 79 1115-1121
70 Ciotta L, Cianci A, Calogero A E. et al . Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril . 1995; 64 299-306
71 Ogawa H, Hattori M. Regulation mechanisms of hair growth. Curr Probl Dermatol . 1983; 11 159-170
72 Hynd P L, Nancarrow M J. Inhibition of polyamine synthesis alters hair follicle function and fiber composition. J Invest Dermatol . 1996; 106 249-253
73 Schrode K, Huber F, Staszak J. et al .Randomized, double-blind, vehicle-controlled safety and efficacy evaluation of eflornithine 15% cream in the treatment of women with excessive facial hair. Poster presented at American Academy of Dermatology Annual Meeting; March 11-14, 2000; San Francisco
74 Patient information leaflet and prescribing information for Vaniqa (Bristol-Myers Squibb) Available at: http//www.vaniqa.com/pdf/pi.pdf .
75 Oh H-S, Smart R C. An estrogen receptor pathway regulated the telogen-anagen hair follicle transition and influences epidermal cell proliferation. Proc Natl Acad Sci U S A . 1996; 93 12525-12530
76 Olsen E. Methods of hair removal. J Am Acad Dermatol . 1999; 40 143-155
77 Schoen L A, Lazar P. The Look You Like. New York: Marcel Dekker 1990: 133-144
78 Ramos-E-Silva M, De Castro C M, Carneiro L V. Hair removal. Clin Dermatol . 2001; 19 437-444
79 Dierickx C. Hair removal by lasers and intense pulsed light sources. Semin Cutan Med Surg . 2000; 19 267-275
80 Dierickx C, Alora M B, Dover J S. Laser hair removal. Dermatol Clin . 1999; 17 357-366
81 Draelos Z. Cosmetics: an overview. Curr Probl Dermatol . 1995; 7 43-64
82 Anderson R R, Parrish J A. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science . 1983; 220 24-27
83 Grossman M C, Dwyer P, Wiberley J. et al . PDT for hirsutism. Lasers Surg Med . 1995; 7(suppl) 44-47
84 Wheeland R G. Laser-assisted hair removal. Dermatol Clin . 1997; 15 469-477